The FDA extended its review of Novo’s hemophilia A injection denecimig after identifying issues at an unnamed manufacturing facility. The agency attributed the delay to “ongoing facility remediation activities” seen during a pre-license inspection, according to the regulator’s rationale. For companies nearing a potential approval decision, manufacturing inspections can become a gating item that changes timing without altering the clinical dataset. A delay can also shift payer discussions, hospital contracting, and competitive positioning for alternative factor and gene-therapy approaches. The episode highlights how late-stage regulatory timelines remain sensitive to production quality systems, remediation schedules, and the pace of remediation verification.